Overview
- Editors:
-
-
Ronald M. Bukowski
-
Experimental Therapeutics, Cleveland Clinic Taussig Cancer Center, Cleveland, USA
-
Andrew C. Novick
-
Department of Urology, Cleveland Clinic Foundation, Cleveland, USA
Access this book
Other ways to access
Table of contents (26 chapters)
-
Management of Advanced and/or Metastatic Renal Cell Carcinoma
-
- John H. Suh, Gene H. Barnett
Pages 269-282
-
- Javier A. Ruiz, Haralambos Raftopoulos, Daniel P. Petrylak
Pages 283-300
-
- Thomas Olencki, Ronald M. Bukowski
Pages 301-318
-
- Robert J. Motzer, William J. Berg
Pages 319-329
-
- Jens Atzpodien, J. Janssen, J. Buer, S. Sel, K. Oevermann
Pages 331-341
-
- Egbert Oosterwijk, Chetan R. Divgi, Martijn S. Steffens, Neil H. Bander
Pages 343-358
-
- Barbara J. Gitlitz, Arie S. Belldegrun, Robert A. Figlin
Pages 359-379
-
- Kevin R. Bigelow, Michael T. Spiotto, Walter M. Stadler
Pages 381-395
-
-
-
Back Matter
Pages 425-434
About this book
Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled.
Reviews
"Every aspect of renal cell carcinoma, from basic science to advanced clinical management, is comprehensively covered. . .I firmly believe this is the most complete yet concise "monogram" on the subject of renal cancers. It is a high quality book that would be extremely useful for anyone who manages renal cell carcinomas on a regular basis. The basic science chapters and in particular the chapters on advanced/metastatic renal tumors are extremely well written and informative. This book is the only one of its kind and hence cannot be compared."-Weighted Numerical Score: 95 - 4 Stars!-Doody's Health Science Book Review Journal
"...a concise, well-organized book that discusses nearly every aspect of renal cancer, from epidemiology and pathology to the management of specific clinical situations and recent research in immunotherapy...This book has many strengths. One is its organization. Each chapter is divided into clearly labeled, short subsections, making it highly readable and allowing the reader to locate information on a particular topic efficiently. A second strength is its emphasis on the immunologic features of renal cancer...This excellent book is both useful and readable. Because of its wide scope but concise organization, it will be valuable to nearly everyone interested in renal cancer, including surgical and medical oncologists, clinical investigators, and laboratory investigators."-The New England Journal of Medicine
" The book is clearly written, the illustrations are informative and the references are complete. It's strongest point is the extensive attention paid to the immunologic aspects of RCC."-Annals of Oncology
Editors and Affiliations
-
Experimental Therapeutics, Cleveland Clinic Taussig Cancer Center, Cleveland, USA
Ronald M. Bukowski
-
Department of Urology, Cleveland Clinic Foundation, Cleveland, USA
Andrew C. Novick